FILTER
FILTERED INTERVIEW RESULTS
Eddie Pauline
PRESIDENT AND CEO, OHIO LIFE SCIENCES
"Ohio is increasingly competitive in attracting larger, well-known life science brands, plus our institutions continue to spin out new biotech companies; people across the country are starting to notice."
Takahiro Ueda
CEO, CMIC CMO USA
"Continuous manufacturing is key to our US strategy, differentiating us in the market."
Louis P. Kassa III
CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"Better alignment between institutions and industry can drive innovation, scientific progress, and economic growth in the coming years."
Steve Favaloro
CHAIRMAN AND CEO, GENEZEN
"Investors are finding it difficult to balance early-phase success with the commercialization hurdles ahead."
Dirk Lange
CEO, PYRAMID LABS
"Alignment on business strategy, culture and operational philosophy is now a critical factor in vendor selection."
Siva Samy
CEO & CHIEF PRODUCT STRATEGIST, VALGENESIS
"With continued investments in AI and automation, we are accelerating the industry's shift to digital validation and data-driven decision-making."
Krishna Kanumuri
CEO AND MANAGING DIRECTOR, SAI LIFE SCIENCES
"The demand for seamless phase transitions is growing, with integrated CRDMOs enabling better knowledge transfer and faster development."
Rajiv Anand
FOUNDER AND CEO, QUARTIC.AI
"Digital transformation helps accelerate drug pipelines by reducing workload and increasing efficiency."
Himanshu Gadgil
CEO, ENZENE BIOSCIENCES
"From an innovation point of view, breaking the US$40/gram cost barrier for production of mAbs is a key objective this year."
Mike Radomsky
PRESIDENT, CMC PHARMACEUTICALS
"We balance the need for speed in drug development with strict regulatory requirements by focusing on robust data, sound justifications and a well-structured technical package."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
